Q32 Bio shares surge 109.59% intraday after selling ADX-097 to Akebia for $12M upfront, extending cash runway to 2027.

Q32 Bio (NASDAQ: QTTB) surged 109.59% intraday following the announcement of a $592 million deal to sell its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics. The transaction includes $12 million in upfront and near-term milestone payments, extending Q32 Bio’s cash runway into late 2027 and enabling focused development of its lead candidate, bempikibart, for alopecia areata. The non-dilutive funding, combined with potential tiered royalties on future ADX-097 sales, was perceived as a strategic boost to the company’s financial flexibility and therapeutic pipeline prioritization. Analysts highlighted the deal’s significance in de-risking Q32 Bio’s capital structure while retaining ownership of its tissue-targeted complement inhibitor platform. The announcement aligned with positive investor sentiment toward biotech asset sales that enhance operational clarity and milestone-driven revenue potential.